Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

QINPREZO™ (vosaroxin)

Overview

Vosaroxin is an anti-cancer quinolone derivative, or AQD - a class of compounds that has not been used previously for the potential treatment of cancer. We licensed worldwide development and commercialization rights to vosaroxin from Sumitomo Dainippon Pharma Co., Ltd. in 2003.

Our goal is to establish vosaroxin in combination with cytarabine as a new treatment option for patients with relapsed or refractory acute myeloid leukemia (AML). Beyond the primary indication in the Phase 3 VALOR trial, we are exploring the broader potential of vosaroxin in different patient segments within AML through investigator-sponsored trials.

Based on the results of our VALOR trial, investigator-sponsored trials, regulatory and competitive considerations, our financial resources and various other factors, we may further invest in the development and clinical testing of vosaroxin for related disease areas and indications such as other AML populations, myelodysplastic syndrome, other hematologic malignancies and solid tumors.

Click here for more information on vosaroxin's mechanism of action.


Clinical Trials

For more information about vosaroxin clinical trials, please click here.

Presentations

Download presentations members of our team have given at recent conferences and meetings.
Vosaroxin Program Presentations and from Investigator Sponsored Trials

Publications

Download reprints of research and studies which have submitted to scientific and medical journals.
Vosaroxin Program Publications


Most Recent Presentations - Sunesis Trials

click here to download this PDF file Characterization of Patients With Relapsed or Refractory AML in Continued Follow-Up After Treatment With Vosaroxin/Cytarabine vs Placebo/Cytarabine in the VALOR Trial
European Hematology Association Annual Congress
Copenhagen, Denmark
Friday, June 10, 2016

click here to download this PDF file Allogeneic Transplantation for Advanced Acute Myelogenous Leukemia (AML): The Value of Complete Remission
The 2016 ASCO Annual Meeting
Chicago, IL
Monday, June 6, 2016

click here to download this PDF file Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine in the Phase 3 VALOR Study
57th American Society of Hematology Annual Meeting
Orlando, FL
Sunday, December 6, 2015

Most Recent Presentations - Investigator Sponsored Trials

click here to download this PDF file Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (PTS) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
European Hematology Association Annual Congress
Copenhagen, Denmark
Saturday, June 11, 2016

click here to download this PDF filePhase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodyplastic Syndrome (MDS)
57th American Society of Hematology Annual Meeting
Orlando, FL
December 7, 2015

click here to download this PDF fileA Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
57th American Society of Hematology Annual Meeting
Orlando, FL
December 5, 2015